Intellia Therapeutics, Inc.
NTLA
$13.37
-$0.11-0.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 23.02M | 13.78M | 14.25M | 16.63M | 12.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.02M | 13.78M | 14.25M | 16.63M | 12.87M |
| Cost of Revenue | 73.63M | 78.95M | 80.53M | 108.43M | 99.66M |
| Gross Profit | -50.61M | -65.17M | -66.29M | -91.80M | -86.78M |
| SG&A Expenses | 48.10M | 46.31M | 43.71M | 29.01M | 49.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 121.73M | 125.26M | 124.24M | 137.43M | 149.32M |
| Operating Income | -98.71M | -111.48M | -110.00M | -120.81M | -136.45M |
| Income Before Tax | -95.79M | -101.32M | -101.26M | -114.33M | -128.90M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -95.79M | -101.32M | -101.26M | -114.33M | -128.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -95.79M | -101.32M | -101.26M | -114.33M | -128.90M |
| EBIT | -98.71M | -111.48M | -110.00M | -120.81M | -136.45M |
| EBITDA | -96.33M | -109.06M | -107.52M | -118.31M | -133.88M |
| EPS Basic | -0.83 | -0.92 | -0.98 | -1.10 | -1.27 |
| Normalized Basic EPS | -0.50 | -0.59 | -0.62 | -0.68 | -0.77 |
| EPS Diluted | -0.83 | -0.92 | -0.98 | -1.10 | -1.27 |
| Normalized Diluted EPS | -0.50 | -0.59 | -0.62 | -0.68 | -0.77 |
| Average Basic Shares Outstanding | 115.92M | 110.19M | 103.73M | 103.50M | 101.86M |
| Average Diluted Shares Outstanding | 115.92M | 110.19M | 103.73M | 103.50M | 101.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |